• Real-life Management of Patients Eligible for CAR-T Cell Therapy

  NCT06369389

  RecruitingObservationalUpdated Apr 10, 2025
• Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies

  NCT04290000

  RecruitingObservationalUpdated Jun 22, 2026
• CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

  NCT05349201

  CompletedObservationalUpdated Jul 1, 2022
• Long-term Follow-up of Subjects Treated With CAR T Cells

  NCT05024175

  RecruitingObservationalUpdated Mar 16, 2026
• Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

  NCT06392763

  CompletedObservationalUpdated Apr 30, 2024
• Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy

  NCT07609485

  RecruitingObservationalUpdated May 27, 2026

ClinicalTrials.gov ID

NCT04328298

Lead Sponsor

The Lymphoma Academic Research OrganisationOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

5,000Estimated

Last Update Posted

Mar 4, 2026Actual

Start Date

Dec 19, 2019Actual

Primary Completion Date

Dec 19, 2038Estimated

Completion Date

Dec 19, 2038Estimated

Official Title

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Brief Summary

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

• Hematopathology Eligible or CAR-t Cell Treatment

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Retrospective inclusion :

• Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
• If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive

Prospective inclusion :

• Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
• Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
• Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
• If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.

Exclusion Criteria Patient not registered with the social security in France

Observational Model

Cohort

Time Perspective

Other

Lead Sponsor

The Lymphoma Academic Research OrganisationOTHER

Collaborators

Gilead SciencesINDUSTRY

NovartisINDUSTRY

Bristol-Myers SquibbINDUSTRY

alschmidt@chu-angers.fr

olivier.casasnovas@chu-dijon.fr+33 (0)3 80 29 50 41

loschi.m@chu-nice.fr+33 (0)4 92 03 90 25

e.gyan@chu-tours.fr+33 (0)2 47 47 37 12